FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2604492038> ?p ?o ?g. }

• W2604492038 endingPage "53" @default.
• W2604492038 startingPage "47" @default.
• W2604492038 abstract "Objectives: Interferon (IFN) treatment has many neuropsychiatric side effects such as depression and anxiety disorder. Although untreated depression is a major contributor to dosage reduction or premature discontinuation of the IFN treatment, it is found that depressive symptoms among patients undergoing hepatitis C virus (HCV) treatment are commonly overlooked during routine clinical interviews. Besides depression, anxiety disorders are shown to affect adherence to pegylated IFN (Peg-IFN) treatment in patients with hepatitis C. Despite the occurrence of neuropsychiatric side effects of IFN treatment being widely reported in patients with hepatitis C, there are few studies studying patients infected with hepatitis B virus (HBV). The aim of this prospective study was to evaluate the incidence and risk factors of depressive and anxiety disorders that occur during Peg-IFN treatment of patients with HBV.Methods: The sample consisted of volunteer patients who were diagnosed with HBV infection and who were decided to receive IFN treatment. During the study period, all consecutive patients with HBV infection and who would have IFN treatment were informed about the study and invited to participate. Thirty-seven chronic hepatitis B (CHB) patients were recruited for the study, but four of them were excluded due to psychiatric diagnosis at the initiation of the treatment. Therefore, the sample consisted of 33 patients with CHB, meeting the inclusion criteria. The participants had psychiatric assessment before the treatment and at 1st, 3rd, 6th, and 12th months. At each visit, the subjects were assessed with Clinical Global Impressions Scale, Hamilton Rating Scale for Depression (HRSD), and Hamilton Anxiety Rating Scale (HAM-A).Results: Among the 33 patients with HBV, 22 (66.7%) were men. Mean age was 35.97 ± 10.73 years. While follow-up, 6 patients dropped out from the study. Also, 13 patients were excluded from the study as they developed depression and/or anxiety disorder. Mean baseline HRSD and HAM-A scores were smaller than the following visits’ scores. The difference was not statistically significant only for the 12th month assessments. Totally 14 (42.4%) patients developed depression/anxiety disorder during 1 year follow-up. Six (42.86%) of them received the diagnosis at the 1st month, 3 (21.43%) at the 3rd, 4 (28.57%), at 6th months, and 1 (7.14%) at the 12th month. When we compared the patients who developed depression/anxiety disorder with the patients who did not develop any psychiatric disorder, we found that the mean baseline HRSD score (t = 2.303, p = .028) and female percentage (p = .017) were statistically significantly higher in the depression/anxiety disorder group.Conclusions: There is an incidence of 42.4% for depression and/or anxiety disorders during Peg-IFN treatment. Females and patients with subsyndromal depressive symptoms should be referred to a psychiatrist and closely monitored especially for the first three months of the IFN treatment." @default.
• W2604492038 created "2017-04-14" @default.
• W2604492038 creator A5018136575 @default.
• W2604492038 creator A5030581757 @default.
• W2604492038 creator A5054049307 @default.
• W2604492038 creator A5062523881 @default.
• W2604492038 creator A5067799797 @default.
• W2604492038 creator A5068607321 @default.
• W2604492038 creator A5085582108 @default.
• W2604492038 date "2017-01-02" @default.
• W2604492038 modified "2023-10-02" @default.
• W2604492038 title "Depression and anxiety disorders during pegylated interferon treatment in patients with chronic hepatitis B" @default.
• W2604492038 cites W1522136588 @default.
• W2604492038 cites W1880708448 @default.
• W2604492038 cites W1925910633 @default.
• W2604492038 cites W1981407617 @default.
• W2604492038 cites W1986730863 @default.
• W2604492038 cites W1992692012 @default.
• W2604492038 cites W2011235168 @default.
• W2604492038 cites W2012057597 @default.
• W2604492038 cites W2018675123 @default.
• W2604492038 cites W2042701393 @default.
• W2604492038 cites W2046721727 @default.
• W2604492038 cites W2047030504 @default.
• W2604492038 cites W2054028494 @default.
• W2604492038 cites W2067495470 @default.
• W2604492038 cites W2067855438 @default.
• W2604492038 cites W2079520331 @default.
• W2604492038 cites W2084315798 @default.
• W2604492038 cites W2092642105 @default.
• W2604492038 cites W2106097163 @default.
• W2604492038 cites W2130326864 @default.
• W2604492038 cites W2134335328 @default.
• W2604492038 cites W2157877920 @default.
• W2604492038 cites W2159847907 @default.
• W2604492038 cites W2160070901 @default.
• W2604492038 cites W2166281097 @default.
• W2604492038 cites W2173007581 @default.
• W2604492038 cites W2209156328 @default.
• W2604492038 cites W2325408065 @default.
• W2604492038 cites W2411779685 @default.
• W2604492038 cites W2915810710 @default.
• W2604492038 cites W4238079920 @default.
• W2604492038 doi "https://doi.org/10.1080/24750573.2017.1293251" @default.
• W2604492038 hasPublicationYear "2017" @default.
• W2604492038 type Work @default.
• W2604492038 sameAs 2604492038 @default.
• W2604492038 citedByCount "1" @default.
• W2604492038 countsByYear W26044920382022 @default.
• W2604492038 crossrefType "journal-article" @default.
• W2604492038 hasAuthorship W2604492038A5018136575 @default.
• W2604492038 hasAuthorship W2604492038A5030581757 @default.
• W2604492038 hasAuthorship W2604492038A5054049307 @default.
• W2604492038 hasAuthorship W2604492038A5062523881 @default.
• W2604492038 hasAuthorship W2604492038A5067799797 @default.
• W2604492038 hasAuthorship W2604492038A5068607321 @default.
• W2604492038 hasAuthorship W2604492038A5085582108 @default.
• W2604492038 hasBestOaLocation W26044920381 @default.
• W2604492038 hasConcept C118552586 @default.
• W2604492038 hasConcept C126322002 @default.
• W2604492038 hasConcept C139719470 @default.
• W2604492038 hasConcept C162324750 @default.
• W2604492038 hasConcept C203014093 @default.
• W2604492038 hasConcept C2522874641 @default.
• W2604492038 hasConcept C2776408679 @default.
• W2604492038 hasConcept C2776455275 @default.
• W2604492038 hasConcept C2776461080 @default.
• W2604492038 hasConcept C2776867660 @default.
• W2604492038 hasConcept C2778715236 @default.
• W2604492038 hasConcept C2780040827 @default.
• W2604492038 hasConcept C558461103 @default.
• W2604492038 hasConcept C71924100 @default.
• W2604492038 hasConceptScore W2604492038C118552586 @default.
• W2604492038 hasConceptScore W2604492038C126322002 @default.
• W2604492038 hasConceptScore W2604492038C139719470 @default.
• W2604492038 hasConceptScore W2604492038C162324750 @default.
• W2604492038 hasConceptScore W2604492038C203014093 @default.
• W2604492038 hasConceptScore W2604492038C2522874641 @default.
• W2604492038 hasConceptScore W2604492038C2776408679 @default.
• W2604492038 hasConceptScore W2604492038C2776455275 @default.
• W2604492038 hasConceptScore W2604492038C2776461080 @default.
• W2604492038 hasConceptScore W2604492038C2776867660 @default.
• W2604492038 hasConceptScore W2604492038C2778715236 @default.
• W2604492038 hasConceptScore W2604492038C2780040827 @default.
• W2604492038 hasConceptScore W2604492038C558461103 @default.
• W2604492038 hasConceptScore W2604492038C71924100 @default.
• W2604492038 hasIssue "1" @default.
• W2604492038 hasLocation W26044920381 @default.
• W2604492038 hasLocation W26044920382 @default.
• W2604492038 hasOpenAccess W2604492038 @default.
• W2604492038 hasPrimaryLocation W26044920381 @default.
• W2604492038 hasRelatedWork W1411399784 @default.
• W2604492038 hasRelatedWork W1586448152 @default.
• W2604492038 hasRelatedWork W1985395902 @default.
• W2604492038 hasRelatedWork W2017904604 @default.
• W2604492038 hasRelatedWork W2045500730 @default.
• W2604492038 hasRelatedWork W2129522191 @default.
• W2604492038 hasRelatedWork W2330453659 @default.

• next